ATE211766T1 - Gentechnologische herstellung von impfstoffen gegen aids und andere retrovirale krankheiten - Google Patents
Gentechnologische herstellung von impfstoffen gegen aids und andere retrovirale krankheitenInfo
- Publication number
- ATE211766T1 ATE211766T1 AT90914669T AT90914669T ATE211766T1 AT E211766 T1 ATE211766 T1 AT E211766T1 AT 90914669 T AT90914669 T AT 90914669T AT 90914669 T AT90914669 T AT 90914669T AT E211766 T1 ATE211766 T1 AT E211766T1
- Authority
- AT
- Austria
- Prior art keywords
- particles
- vaccines against
- production
- against aids
- retroviral diseases
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 208000030507 AIDS Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002068 genetic effect Effects 0.000 title 1
- 230000001177 retroviral effect Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 239000002245 particle Substances 0.000 abstract 4
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 3
- 108020004414 DNA Proteins 0.000 abstract 1
- 102000053602 DNA Human genes 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 108700004026 gag Genes Proteins 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108700004029 pol Genes Proteins 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/974—Aids related test
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/826—Viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
- Y10S977/803—Containing biological material in its interior
- Y10S977/804—Containing nucleic acid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
- Y10S977/917—Vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/918—Immunological
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/92—Detection of biochemical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/924—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis using nanostructure as support of dna analysis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB898923123A GB8923123D0 (en) | 1989-10-13 | 1989-10-13 | A vaccine for human immunodeficiency virus |
PCT/CA1990/000350 WO1991005864A1 (en) | 1989-10-13 | 1990-10-12 | Production of genetically-engineered vaccines for aids and other retroviral diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE211766T1 true ATE211766T1 (de) | 2002-01-15 |
Family
ID=10664542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT90914669T ATE211766T1 (de) | 1989-10-13 | 1990-10-12 | Gentechnologische herstellung von impfstoffen gegen aids und andere retrovirale krankheiten |
Country Status (10)
Country | Link |
---|---|
US (5) | US5439809A (de) |
EP (1) | EP0495811B1 (de) |
JP (1) | JP2537570B2 (de) |
AT (1) | ATE211766T1 (de) |
CA (1) | CA2067333C (de) |
DE (1) | DE69033896T2 (de) |
DK (1) | DK0495811T3 (de) |
ES (1) | ES2171156T3 (de) |
GB (1) | GB8923123D0 (de) |
WO (1) | WO1991005864A1 (de) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861282A (en) * | 1989-10-16 | 1999-01-19 | Whitehead Institute For Biomedical Research | Non-infectious HIV particles and uses therefor |
CA2068713A1 (en) * | 1989-11-20 | 1991-05-21 | Omar K. Haffar | Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens |
WO1991019803A1 (en) * | 1990-06-19 | 1991-12-26 | Applied Biotechnology, Incorporated | Self assembled, defective, nonself-propagating viral particles |
IL98845A0 (en) * | 1990-07-19 | 1992-07-15 | Merck & Co Inc | Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties,their preparation and pharmaceutical compositions containing them |
US5849475A (en) * | 1990-10-12 | 1998-12-15 | Benjamin Rovinski et al | Immunoassay diagnostic kit containing antigens derived from self-assembled, non-infectious, non-replicating, immunogenic retrovirus-like particles comprising modified HIV genomes and chimeric envelope glycoproteins |
AU702634B2 (en) * | 1991-03-07 | 1999-02-25 | Virogenetics Corporation | Immunodeficiency recombinant poxvirus |
US5863542A (en) * | 1991-03-07 | 1999-01-26 | Virogenetics Corporation | Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts |
FR2676071B1 (fr) * | 1991-05-02 | 1994-11-18 | Transgene Sa | Nouveau variant gp160 non-clivable, soluble, de forme hybride. |
US6268211B1 (en) | 1991-08-20 | 2001-07-31 | L'institut De Recherches Cliniques De Montreal | Non-infectious HIV transgene |
WO1992020790A1 (en) * | 1991-05-15 | 1992-11-26 | L'institut De Recherches Cliniques De Montreal | Transgenic non-human animal carrying a non-infectious hiv genome |
US5274122A (en) * | 1992-10-15 | 1993-12-28 | Merck & Co., Inc. | Acidic derivatives of homocysteine thiolactone |
JPH06261764A (ja) * | 1993-02-17 | 1994-09-20 | Wisconsin Alumni Res Found | 混合型ltr含有超複合型レトロウイルス及びその使用方法 |
US5470572A (en) * | 1993-07-16 | 1995-11-28 | University Of Puerto Rico | Non-infectious simian immunodeficiency virus particles produced by cell line CRL 11393 |
WO1995005851A1 (en) * | 1993-08-20 | 1995-03-02 | St. Luke's-Roosevelt Hospital Center | HIV vif-RELATED COMPOSITIONS, AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF |
US6015661A (en) * | 1994-02-14 | 2000-01-18 | The Macfarlane Burnet Centre For Medical Research Limited | Methods for the detection of non-pathogenic HIV-1 strains containing deletions in the Nef coding region and U3 region of the LTR |
US6291157B1 (en) | 1998-02-23 | 2001-09-18 | Connaught Laboratories Limited | Antigenically-marked non-infectious retrovirus-like particles |
US5858838A (en) | 1998-02-23 | 1999-01-12 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method for increasing DRAM capacitance via use of a roughened surface bottom capacitor plate |
US5955342A (en) * | 1994-08-15 | 1999-09-21 | Connaught Laboratories Limited | Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region |
US6080408A (en) | 1994-08-22 | 2000-06-27 | Connaught Laboratories Limited | Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles |
DE69526260T2 (de) * | 1994-11-15 | 2002-10-17 | Powderject Vaccines Inc | Methode zur induktion der humoralen und zellulären immunantwort durch intrazelluläre zufuhr von peptidbeschichteten mikropartikeln |
CN1185811A (zh) * | 1995-03-31 | 1998-06-24 | H·沃尔夫 | 依赖于逆转录病毒样颗粒的抗原呈递系统 |
NZ331376A (en) * | 1996-01-29 | 2000-03-27 | Virologic Inc | Methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
US6242187B1 (en) * | 1996-01-29 | 2001-06-05 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
US6024965A (en) * | 1996-10-18 | 2000-02-15 | Erasums University Rotterdam | Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection |
WO1998043669A1 (en) * | 1997-04-03 | 1998-10-08 | Thomas Jefferson University | Chimeric viral proteins |
CN1239512A (zh) * | 1997-08-07 | 1999-12-22 | 奥尔特威尔生物技术公司 | 脊髓灰质炎病毒具有复制能力的重组体萨宾i型株系 |
US20050033022A1 (en) * | 1997-09-26 | 2005-02-10 | Smithkline Beecham Biologicals Sa | Fusion proteins comprising HIV-1 Tat and/or Nef proteins |
US6121021A (en) | 1997-12-16 | 2000-09-19 | Connaught Laboratories Limited | Constitutive expression of non-infectious HIV-like particles |
US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
EP1078105B1 (de) | 1998-05-12 | 2004-11-24 | Genecure LLC | Replikationsdefekter hiv impfstoff |
AU762376C (en) * | 1998-08-04 | 2004-10-14 | Henry M. Jackson Foundation, The | Expression and characterization of HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response |
US7090848B1 (en) * | 1998-08-04 | 2006-08-15 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response |
US6764676B1 (en) | 1998-08-24 | 2004-07-20 | Pfizer Inc. | Compositions and methods for protecting animals from lentivirus-associated disease such as feline immunodeficiency virus |
US20040105871A1 (en) * | 2000-03-02 | 2004-06-03 | Robinson Harriet L. | Compositions and methods for generating an immune response |
US8623379B2 (en) * | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
AU1194802A (en) | 2000-03-02 | 2001-12-11 | Univ Emory | DNA expression vectors and methods of use |
EP1776961A1 (de) * | 2000-04-27 | 2007-04-25 | Sanofi Pasteur Limited | Impfung gegen HIV |
DE60125927T2 (de) * | 2000-04-27 | 2007-10-18 | Sanofi Pasteur Ltd., Toronto | Impfstoffe gegen hiv |
US6585978B1 (en) * | 2000-09-09 | 2003-07-01 | Akzo Nobel | EIA vaccine and diagnostic |
US6461616B1 (en) * | 2000-09-09 | 2002-10-08 | Akzo Nobel Nv | EIAV p26 deletion vaccine and diagnostic |
US7122180B2 (en) * | 2000-10-23 | 2006-10-17 | Children's Medical Center Corporation | DNA vectors containing mutated HIV proviruses |
AU2002252199B2 (en) * | 2001-03-08 | 2008-01-03 | Emory University | MVA expressing modified HIV envelope, GAG, and POL genes |
FR2824072B1 (fr) * | 2001-04-27 | 2004-03-12 | Centre Nat Rech Scient | Procede de replication et de production du virus de l'hepatite c |
US7943146B2 (en) * | 2001-12-21 | 2011-05-17 | Myrexis, Inc. | Immunizing compositions comprising HIV-1 proviral constructs with an inactive p6 gag TSG101 UEV binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface |
WO2004065575A2 (en) * | 2003-01-15 | 2004-08-05 | Research Institute For Genetic And Human Therapy (Right) | Dna compositon and uses thereof |
CA2537953A1 (en) * | 2003-09-09 | 2005-03-17 | Virxsys Corporation | Lentivirus vector-based approaches for generating an immune response to hiv in humans |
US20050222068A1 (en) | 2003-10-23 | 2005-10-06 | Mourich Dan V | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells |
US20070135620A1 (en) * | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
CA2587617C (en) | 2004-11-12 | 2011-02-01 | Xencor, Inc. | Fc variants with altered binding to fcrn |
WO2006118615A2 (en) * | 2004-12-16 | 2006-11-09 | Brandeis University | Clonable tag for purification and electron microscopy labeling |
US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
US9216212B2 (en) * | 2005-08-05 | 2015-12-22 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
US9593340B2 (en) * | 2007-10-15 | 2017-03-14 | Admedus Vaccines Pty Ltd. | Expression system for modulating an immune response |
EP2376633A1 (de) | 2008-12-17 | 2011-10-19 | AVI BioPharma, Inc. | Antisense-zusammensetzungen und verfahren zur modulation von kontaktüberempfindlichkeit oder kontaktdermatitis |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
US9795658B2 (en) | 2010-04-20 | 2017-10-24 | Admedus Vaccines Pty Ltd | Expression system for modulating an immune response |
PT2694101T (pt) | 2011-04-06 | 2016-12-19 | Université Paris Descartes | Composições farmacêutivas para prevenção e/ou tratamento de doença por vih em seres humanos |
HUE037408T2 (hu) | 2011-06-10 | 2018-08-28 | Univ Oregon Health & Science | CMV glikoproteinek és rekombináns vektorok |
AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
EP2586461A1 (de) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Von einem eingehüllten Virus abgeleitete Virenpartikel |
SG11201404711WA (en) | 2012-02-16 | 2014-09-26 | Vlp Therapeutics Llc | Virus like particle composition |
ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
US9730996B2 (en) * | 2012-10-24 | 2017-08-15 | Texas Biomedical Research Institute | Involucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins |
TWI676636B (zh) | 2013-07-12 | 2019-11-11 | Vlp醫療股份有限公司 | 包含pd-1抗原或pd-1配體抗原的類病毒粒子 |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
JP6824154B2 (ja) | 2014-08-08 | 2021-02-03 | ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーVLP Therapeutics, LLC | 修飾エンベロープタンパク質e3を含むウイルス様粒子 |
CA2960102C (en) | 2014-09-11 | 2023-10-24 | Vlp Therapeutics, Llc | Flavivirus virus like particle |
EP3069730A3 (de) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
EP3072901A1 (de) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
CA3006779A1 (en) | 2015-12-09 | 2017-06-15 | Admedus Vaccines Pty Ltd | Immunomodulating composition for treatment |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59104325A (ja) * | 1982-12-07 | 1984-06-16 | Japan Found Cancer | ヒト白血病ウイルスの遺伝子rnaに相補性を示すdna |
US4722840A (en) * | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
NZ217645A (en) * | 1985-09-25 | 1991-11-26 | Oncogen | Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations |
ZA867281B (en) * | 1985-09-25 | 1987-05-27 | Oncogen | Vaccines and immunoassays for acquired immune deficiency syndrome |
US4925784A (en) * | 1986-04-04 | 1990-05-15 | Hoffmann-La Roche Inc. | Expression and purification of an HTLV-III gag/env gene protein |
US4752565A (en) * | 1986-04-07 | 1988-06-21 | The United States Of America As Represented By The Department Of Health And Human Services | Cell line producing AIDS viral antigens without producing infectious virus particles |
EP0329671B1 (de) * | 1986-11-01 | 1994-01-12 | British Bio-Technology Limited | Kugelförmige hybrid-hiv-antigene |
JPH01120284A (ja) * | 1987-11-05 | 1989-05-12 | Shiro Kato | Hiv不完全粒子および該製造方法 |
IL89567A0 (en) * | 1988-03-28 | 1989-09-10 | Univ Leland Stanford Junior | Mutated hiv envelope protein |
AU3775789A (en) * | 1988-06-10 | 1990-01-05 | Applied Biotechnology, Inc. | A method of evaluating recombinant vaccines against immunodeficiency virus |
US5019752A (en) | 1988-06-16 | 1991-05-28 | Hughes Aircraft Company | Plasma switch with chrome, perturbated cold cathode |
JPH02203783A (ja) * | 1989-02-02 | 1990-08-13 | Banyu Pharmaceut Co Ltd | 抗原性を有する非感染性エイズウイルス産生クローン化ヒトt細胞 |
JP3140757B2 (ja) * | 1989-02-06 | 2001-03-05 | デイナ・フアーバー・キヤンサー・インステイテユート | パッケージング欠陥hivプロウイルス、細胞系及びその使用 |
EP1288304A3 (de) * | 1989-06-01 | 2006-04-05 | Applied Biotechnology, Inc. | Selbstzusammengesetzte, Defekte, sich Nichtselbstvermehrende |
JP2897295B2 (ja) * | 1989-12-14 | 1999-05-31 | 味の素株式会社 | レトロウィルス高生産用dna構築物及びレトロウィルス高生産用細胞株 |
WO1991019803A1 (en) * | 1990-06-19 | 1991-12-26 | Applied Biotechnology, Incorporated | Self assembled, defective, nonself-propagating viral particles |
-
1989
- 1989-10-13 GB GB898923123A patent/GB8923123D0/en active Pending
-
1990
- 1990-10-12 DK DK90914669T patent/DK0495811T3/da active
- 1990-10-12 ES ES90914669T patent/ES2171156T3/es not_active Expired - Lifetime
- 1990-10-12 WO PCT/CA1990/000350 patent/WO1991005864A1/en active IP Right Grant
- 1990-10-12 CA CA002067333A patent/CA2067333C/en not_active Expired - Lifetime
- 1990-10-12 AT AT90914669T patent/ATE211766T1/de not_active IP Right Cessation
- 1990-10-12 JP JP2513524A patent/JP2537570B2/ja not_active Expired - Lifetime
- 1990-10-12 DE DE69033896T patent/DE69033896T2/de not_active Expired - Lifetime
- 1990-10-12 EP EP90914669A patent/EP0495811B1/de not_active Expired - Lifetime
-
1992
- 1992-06-15 US US07/839,751 patent/US5439809A/en not_active Expired - Lifetime
-
1994
- 1994-05-06 US US08/239,427 patent/US5571712A/en not_active Expired - Lifetime
-
1995
- 1995-03-09 US US08/401,355 patent/US6291227B1/en not_active Expired - Lifetime
- 1995-06-06 US US08/467,975 patent/US5985641A/en not_active Expired - Lifetime
-
1999
- 1999-09-03 US US09/389,364 patent/US7008784B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0495811A1 (de) | 1992-07-29 |
JPH04506301A (ja) | 1992-11-05 |
US5571712A (en) | 1996-11-05 |
CA2067333C (en) | 2001-05-01 |
ES2171156T3 (es) | 2002-09-01 |
DE69033896D1 (de) | 2002-02-14 |
WO1991005864A1 (en) | 1991-05-02 |
DE69033896T2 (de) | 2002-11-14 |
DK0495811T3 (da) | 2002-02-11 |
US6291227B1 (en) | 2001-09-18 |
US7008784B1 (en) | 2006-03-07 |
GB8923123D0 (en) | 1989-11-29 |
US5985641A (en) | 1999-11-16 |
JP2537570B2 (ja) | 1996-09-25 |
US5439809A (en) | 1995-08-08 |
EP0495811B1 (de) | 2002-01-09 |
CA2067333A1 (en) | 1991-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE211766T1 (de) | Gentechnologische herstellung von impfstoffen gegen aids und andere retrovirale krankheiten | |
Franchini et al. | Human T-cell leukemia virus (HTLV-I) transcripts in fresh and cultured cells of patients with adult T-cell leukemia. | |
Zhang et al. | Lentiviral vectors for sustained transgene expression in human bone marrow–derived stromal cells | |
EP2222861B1 (de) | Polypurintrakt-modifizierte retrovirusvektoren | |
Cichutek et al. | Development of a quasispecies of human immunodeficiency virus type 1 in vivo. | |
DE69829471D1 (de) | Auf lentivirus basierende gentransfer-vektoren | |
DE69435316D1 (de) | Verfahren zur herstellung von hohen virustitern und die hocheffiziente transduktion von säugerzellen durch retroviren | |
WO1989005349A1 (en) | Method of combating viral infections | |
DE3853422T2 (de) | HIV-3-Retrovirus und seine Verwendung. | |
EP1035210A3 (de) | Von SIVagm abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen | |
CA2328404A1 (en) | Novel lentiviral packaging cells | |
NO921969L (no) | Ikke-replikerende rekombinant fremstilte retroviruspartikler brukt som antivirale midler og immunogener | |
CN114941011A (zh) | 慢病毒载体及其应用 | |
CA2422544A1 (en) | Conditionally replicating viral vectors and their use | |
CN106399376A (zh) | 一种整合缺陷型慢病毒载体、其制备方法及应用 | |
Blancou et al. | Simian immunodeficiency virus promoter exchange results in a highly attenuated strain that protects against uncloned challenge virus | |
MY104530A (en) | Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses. | |
RU2006123079A (ru) | Вирусные частицы, содержащие вектор, происходящий из альфавируса, и способ получения указанной вирусной частицы | |
EP2128256A3 (de) | Molekulare Klone mit mutierten HIV-GAG/POL-, SIV-GAG- und SIV-ENV-Genen | |
DE3789545T2 (de) | Impfstoff bestehend aus einem Virusvektor und Rekombinanten-DNS, die das p25-Protein vom AIDS-Virus kodieren. | |
CA2209135C (en) | Human immunodeficiency virus vaccines and therapeutics containing replication-impaired hiv-1 nef-deletion mutants | |
AU5138293A (en) | Recombinant retroviral vector against felv and/or fiv | |
Cann | Stable and safe HIV provirus clones. | |
ATE417108T1 (de) | Hiv-2 und siv-1 nukleotidsequenzen | |
Krohn et al. | Transcomplementation of simian immunodeficiency virus Rev with human T-cell leukemia virus type I Rex |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
EELA | Cancelled due to lapse of time |